- Home
- TMDX vs TERN Comparison
TMDX vs TERN Comparison
Compare TMDX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMDX | TERN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TMDX | TERN |
|---|---|---|
| Price | $123.69 | $41.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $144.25 | $48.60 |
| AVG Volume (30 Days) | 724.8K | ★ 4.6M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $566,354,000.00 | N/A |
| Revenue This Year | $38.81 | N/A |
| Revenue Next Year | $20.49 | N/A |
| P/E Ratio | $48.97 | ★ N/A |
| Revenue Growth | ★ 41.20 | N/A |
| 52 Week Low | $55.00 | $1.87 |
| 52 Week High | $156.00 | $48.26 |
Technical Indicators
Market Signals| Indicator | TMDX | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 66.73 |
| Support Level | $120.82 | $39.15 |
| Resistance Level | $133.29 | $42.97 |
| Average True Range (ATR) | 5.52 | 3.58 |
| MACD | -0.91 | -0.70 |
| Stochastic Oscillator | 19.55 | 63.29 |
Price Performance
Historical ComparisonAbout TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.